Teva Pharmaceutical Industries Ltd (NYSE: TEVA) is reportedly considering potential strategic options for its active pharmaceutical ingredients (API) unit, which could include a potential sale.
This news comes from individuals privy to the matter, who indicated that the current healthcare asset acquisitions continue despite the broader global slowdown in dealmaking.
Working with consultants, Teva is attempting to identify potential buyers for its API unit, which could be valued at approximately $2 billion in a potential transaction.
Also Read: ADHD Medication Shortage Worsens, Vyvanse Supply Dwindles Amid …
